CClinicalTrials.gg
CompletedNCT06027034Updated Jun 16, 2026

Effectiveness of a Digital Health Application for Psoriasis

An interventional study of Online program for psoriasis (GAIA-PSO-01) in Psoriasis, sponsored by Gaia AG. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Gaia AG · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
348
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial with 348 patients with psoriasis aims to investigate the effectiveness of a self-guided online program for patients with psoriasis.

Patients will be randomized and allocated in a 1:1 ratio to either an intervention group, in which they will receive 12-month-access to an online program for psoriasis in addition to treatment as usual (TAU, n = 174), or to a control group, in which they will receive only TAU (n = 174). TAU is defined as any therapy prescribed or recommended by the GP or specialists (e.g. dermatologist, psychiatrist), which may include topical therapy, phototherapy, pharmacotherapy, psychosocial therapy, etc.

02

Conditions studied

  • Psoriasis

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age ≥ 18 years
  • Presence of psoriasis vulgaris or psoriatic arthritis
  • Submission of a specialist medical certificate attesting to the presence of at least one of the following ICD-10-GM diagnoses: Psoriasis vulgaris (L 40.0, L 40.7), Psoriatic arthritis (L40.5, M07.x)
  • Impaired health-related quality of life (DLQI > 10)
  • Consent to participate
  • Sufficient understanding of the German language

Exclusion criteria

Exclusion Criteria:

  • Presence of another subtype of psoriasis (pustular psoriasis, guttate psoriasis, inverse psoriasis, erythrodermic psoriasis, or drug-induced psoriasis) or psoriatic arthritis without skin involvement
  • Presence of malignancies
  • Presence of other chronic diseases with strong negative influence on quality of life
  • Currently undergoing psychiatric treatment / current presence of a severe psychiatric diagnosis
  • Insufficient language and/or IT skills
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
348 participants (actual)

Study arms

  • Experimental
    Online program for psoriasis (GAIA-PSO-01) + TAU

    Participants allocated to the intervention group will receive access to an online program for psoriasis (GAIA-PSO-01) in addition to treatment as usual (TAU).

    Behavioral: Online program for psoriasis (GAIA-PSO-01)

  • No intervention
    TAU

    Participants allocated to the control group will receive access to treatment as usual (TAU).

Interventions

  • BehavioralOnline program for psoriasis (GAIA-PSO-01)

    The program to-be-tested (GAIA-PSO-01) is an interactive online program for independent use by users with psoriasis. It focuses on recognized treatment elements of cognitive behavioral therapy (CBT) and behavior change techniques.

05

What researchers measure

Primary outcomes

  1. Health-Related Quality of Life

    Total score of the Dermatology Life Quality Index (DLQI). Total score ranging from 0-30; higher scores mean a worse outcome.

    Time frame: 3 months

Secondary outcomes

  1. Psoriasis Severity

    Total score of the Self-Administered Psoriasis Area Severity Index (PASI). Total score ranging from 0-72; higher scores mean a worse outcome.

    Time frame: 3 months, 6 months, 12 months

  2. Depressive Symptoms

    Total score of the Patient Health Questionnaire (PHQ-9). Total score ranging from 0-27; higher scores mean a worse outcome.

    Time frame: 3 months, 6 months, 12 months

  3. Body Surface Area (BSA)

    Body Surface Area (BSA) is a measure used to determine the extent of skin involvement in psoriasis. Total score ranging from 0-100; higher scores mean a worse outcome.

    Time frame: 3 months, 6 months, 12 months

  4. Health-Related Quality of Life

    Total score of the Dermatology Life Quality Index (DLQI). Total score ranging from 0-30; higher scores mean a worse outcome.

    Time frame: 6 months, 12 months

Other outcomes

  1. Patient Activation

    Total score of the Patient Activation Measure-13 (PAM-13). Total score ranging from 0-100; higher scores mean a better outcome.

    Time frame: 3 months, 6 months, 12 months

  2. Self-Esteem

    Total score of the Rosenberg Self-Esteem Scale (RSE). Total score ranging from 0-30; higher scores mean a better outcome.

    Time frame: 3 months, 6 months, 12 months

  3. Body Mass Index

    Body mass index (BMI) is a simple measure of body fat based on height and weight. Higher values mean a worse outcome.

    Time frame: 3 months, 6 months, 12 months

  4. Alcohol Consumption

    Total score of the Alcohol use Disorders Identification Test - Consumption Items (AUDIT-C). Total score ranging from 0-12; higher scores mean a worse outcome.

    Time frame: 3 months, 6 months, 12 months

  5. Cigarette Smoking

    Cigarette smoking will be assessed with a single question 'How often do you smoke cigarettes?', with response options 'Never/rarely/sometimes/often/very often', coded from 0-4. Higher scores mean a worse outcome.

    Time frame: 3 months, 6 months, 12 months

06

Study locations

1 site
  • GAIA AG
    Hamburg, Free and Hanseatic City of Hamburg 22085, Germany
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06027034
Lead sponsor
Gaia AG
Collaborators
University of Giessen, Universitätsklinikum Hamburg-Eppendorf
Responsible party
Sponsor
First posted
Sep 7, 2023
Start date
Sep 4, 2023
Primary completion
Dec 31, 2024
Completion
Dec 11, 2025
Last update
Jun 16, 2026

Study contacts

Uwe Gieler, Prof. Dr.
principal investigator · University of Giessen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion